Product Description
ABT-925 is a selective dopamine D_ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D_ versus D_ receptors.ÊFor patients with acute schizophrenia (Sourced from: https://pubmed.ncbi.nlm.nih.gov/21346607/)
Mechanisms of Action: D3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00412620 |
M06-816 | P2 |
Terminated |
Schizophrenia |
2007-10-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|